Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants

W. E. Dager, A. J. Roberts, Daniel Nishijima

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Management of acute, major or life threatening bleeding in the presence of direct acting oral anticoagulants (DOAC) is unclear. In the absence of a specific antidote, or in situations where there is a need for adjunctive therapy, the ideal prothrombin complex concentrate and dose is unclear. The goal of our study was to evaluate the outcomes of our reduced dosing strategy with FEIBA in patients experiencing a DOAC-related bleeding event. Design: Retrospective analysis of patients treated with FEIBA for a DOAC-related bleeding event. Setting: Academic medical center Patients: Consecutive patients between May 2011 and April 2017 receiving FEIBA for a DOAC-related bleed Interventions: None Measurements & main results: Of the 64 patients included in this analysis, 38 patients received low dose FEIBA (mean 10.0 ± 3.6 units/kg) and 26 received moderate dose (mean 24.3 ± 2.1 units/kg) FEIBA; an additional dose was requested in 6 patients. Six dabigatran patients received idarucizumab. 30 day event rates included 5 thromboembolic events (8%) and 9 (14%) patients expired. Follow-up CT-imaging for ICH, endoscopy/colonoscopy, or interventional radiology exams did not reveal any clinically concerning active bleeding or hematoma expansion except in 2 ICH patients with slight expansion between imaging sessions. Conclusions: Low (<20 units/kg) to moderate (20–30 units/kg) doses of FEIBA, with the option for a repeat dose, may be an effective management strategy for obtaining hemostasis in DOAC-related major bleeding events.

Original languageEnglish (US)
Pages (from-to)71-76
Number of pages6
JournalThrombosis Research
Volume173
DOIs
StatePublished - Jan 1 2019

Fingerprint

Anticoagulants
Hemorrhage
Interventional Radiology
Antidotes
Colonoscopy
Hemostasis
Hematoma
Endoscopy

Keywords

  • Anticoagulation
  • Apixaban
  • Dabigatran
  • FEIBA
  • Reversal
  • Rivaroxaban

ASJC Scopus subject areas

  • Hematology

Cite this

Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. / Dager, W. E.; Roberts, A. J.; Nishijima, Daniel.

In: Thrombosis Research, Vol. 173, 01.01.2019, p. 71-76.

Research output: Contribution to journalArticle

@article{aa8274ae39cc48f5a5d48a42dfb9cb47,
title = "Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants",
abstract = "Objective: Management of acute, major or life threatening bleeding in the presence of direct acting oral anticoagulants (DOAC) is unclear. In the absence of a specific antidote, or in situations where there is a need for adjunctive therapy, the ideal prothrombin complex concentrate and dose is unclear. The goal of our study was to evaluate the outcomes of our reduced dosing strategy with FEIBA in patients experiencing a DOAC-related bleeding event. Design: Retrospective analysis of patients treated with FEIBA for a DOAC-related bleeding event. Setting: Academic medical center Patients: Consecutive patients between May 2011 and April 2017 receiving FEIBA for a DOAC-related bleed Interventions: None Measurements & main results: Of the 64 patients included in this analysis, 38 patients received low dose FEIBA (mean 10.0 ± 3.6 units/kg) and 26 received moderate dose (mean 24.3 ± 2.1 units/kg) FEIBA; an additional dose was requested in 6 patients. Six dabigatran patients received idarucizumab. 30 day event rates included 5 thromboembolic events (8{\%}) and 9 (14{\%}) patients expired. Follow-up CT-imaging for ICH, endoscopy/colonoscopy, or interventional radiology exams did not reveal any clinically concerning active bleeding or hematoma expansion except in 2 ICH patients with slight expansion between imaging sessions. Conclusions: Low (<20 units/kg) to moderate (20–30 units/kg) doses of FEIBA, with the option for a repeat dose, may be an effective management strategy for obtaining hemostasis in DOAC-related major bleeding events.",
keywords = "Anticoagulation, Apixaban, Dabigatran, FEIBA, Reversal, Rivaroxaban",
author = "Dager, {W. E.} and Roberts, {A. J.} and Daniel Nishijima",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.thromres.2018.11.009",
language = "English (US)",
volume = "173",
pages = "71--76",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants

AU - Dager, W. E.

AU - Roberts, A. J.

AU - Nishijima, Daniel

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Management of acute, major or life threatening bleeding in the presence of direct acting oral anticoagulants (DOAC) is unclear. In the absence of a specific antidote, or in situations where there is a need for adjunctive therapy, the ideal prothrombin complex concentrate and dose is unclear. The goal of our study was to evaluate the outcomes of our reduced dosing strategy with FEIBA in patients experiencing a DOAC-related bleeding event. Design: Retrospective analysis of patients treated with FEIBA for a DOAC-related bleeding event. Setting: Academic medical center Patients: Consecutive patients between May 2011 and April 2017 receiving FEIBA for a DOAC-related bleed Interventions: None Measurements & main results: Of the 64 patients included in this analysis, 38 patients received low dose FEIBA (mean 10.0 ± 3.6 units/kg) and 26 received moderate dose (mean 24.3 ± 2.1 units/kg) FEIBA; an additional dose was requested in 6 patients. Six dabigatran patients received idarucizumab. 30 day event rates included 5 thromboembolic events (8%) and 9 (14%) patients expired. Follow-up CT-imaging for ICH, endoscopy/colonoscopy, or interventional radiology exams did not reveal any clinically concerning active bleeding or hematoma expansion except in 2 ICH patients with slight expansion between imaging sessions. Conclusions: Low (<20 units/kg) to moderate (20–30 units/kg) doses of FEIBA, with the option for a repeat dose, may be an effective management strategy for obtaining hemostasis in DOAC-related major bleeding events.

AB - Objective: Management of acute, major or life threatening bleeding in the presence of direct acting oral anticoagulants (DOAC) is unclear. In the absence of a specific antidote, or in situations where there is a need for adjunctive therapy, the ideal prothrombin complex concentrate and dose is unclear. The goal of our study was to evaluate the outcomes of our reduced dosing strategy with FEIBA in patients experiencing a DOAC-related bleeding event. Design: Retrospective analysis of patients treated with FEIBA for a DOAC-related bleeding event. Setting: Academic medical center Patients: Consecutive patients between May 2011 and April 2017 receiving FEIBA for a DOAC-related bleed Interventions: None Measurements & main results: Of the 64 patients included in this analysis, 38 patients received low dose FEIBA (mean 10.0 ± 3.6 units/kg) and 26 received moderate dose (mean 24.3 ± 2.1 units/kg) FEIBA; an additional dose was requested in 6 patients. Six dabigatran patients received idarucizumab. 30 day event rates included 5 thromboembolic events (8%) and 9 (14%) patients expired. Follow-up CT-imaging for ICH, endoscopy/colonoscopy, or interventional radiology exams did not reveal any clinically concerning active bleeding or hematoma expansion except in 2 ICH patients with slight expansion between imaging sessions. Conclusions: Low (<20 units/kg) to moderate (20–30 units/kg) doses of FEIBA, with the option for a repeat dose, may be an effective management strategy for obtaining hemostasis in DOAC-related major bleeding events.

KW - Anticoagulation

KW - Apixaban

KW - Dabigatran

KW - FEIBA

KW - Reversal

KW - Rivaroxaban

UR - http://www.scopus.com/inward/record.url?scp=85056987500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056987500&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2018.11.009

DO - 10.1016/j.thromres.2018.11.009

M3 - Article

VL - 173

SP - 71

EP - 76

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -